NCT04552743: Phase 2: MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for ASCT
Updated: May 24, 2022
NCT04552743: Phase 2: MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma
MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma
This research study tests a new medicine for mobilizing stem cells so they can be collected and used for autologous stem cell transplant for treatment of multiple myeloma. MGTA-145, the new medicine, will be given with plerixafor.
Sponsor
Stanford University
ClinicalTrials.gov Identifier: NCT04552743
Official Title: Phase II Study of MGTA-145 in Combination With Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Patients With Multiple Myeloma
First Posted : September 17, 2020
Click here to see details on ClinicalTrials.gov
Drug: MGTA-145
Drug: Plerixafor
CXCR2 Agonist MGTA-145 (Code C176851)
CXCR2 Agonist MGTA-145
GRO-beta
GROb
MGTA 145
MGTA-145
MGTA145
Location
United States, California